Naxitamab
Naxitamab
Definition
A humanized monoclonal antibody directed against the human tumor-associated antigen GD2, with potential antineoplastic activity. Upon vaccination, naxitamab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against GD2-expressing tumor cells. GD2, a disialoganglioside with expression in normal tissues restricted primarily to the cerebellum and peripheral nerves, is commonly expressed at high levels on tumors of neuroectodermal origins such as melanomas and neuroblastomas. Compared to the murine monoclonal antibody 3F8 (m3F8), the humanized form does not cause a human anti-mouse antibody (HAMA) response and shows enhanced ADCC activity.
Also known as Anti-Gd2 IGG3 Monoclonal Antibody 3f8 Humanized, Danyelza, Hu3F8, Humanized Anti-GD2 Antibody 3F8, Humanized Monoclonal Antibody Hu3f8-IGG1, NAXITAMAB, Naxitamab-gqgk — per NCIT
Also identified as
- ATC L01FX21 per RXNORM
- NCIT NCIT:C123428 per NCIT
- SCTID 1137637004 per RXNORM
- SCTID 1137667005 per RXNORM
- UNII 9K8GNJ2874 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Neuroblastoma | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Nervous system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.